AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36064432 — intervention group
Group type: COMPARATOR
Intervention: HTO combined with normal saline (NS)
Number of subjects: 74
Study 35434156 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shockwave therapy (ESWT) along with routine care (CB)
Number of subjects: 50
Study 35434156 — intervention group
Group type: COMPARATOR
Intervention: Sham ESWT along with routine care (CB)
Number of subjects: 50
Study 34210730 — intervention group
Group type: EXPERIMENTAL
Intervention: GeMuKi lifestyle intervention (counselling using motivational interviewing techniques)
Number of subjects: 1860
Study 34210730 — intervention group
Group type: EXPERIMENTAL
Intervention: GeMuKi lifestyle intervention
Number of subjects: 1860
Study 32457082 — intervention group
Group type: EXPERIMENTAL
Intervention: EPOCH bundle added to standard care
Number of subjects: 0
Study 32457082 — intervention group
Group type: COMPARATOR
Intervention: Standard care only
Number of subjects: 0
Study 36215327 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital home exercise program (12-week duration, 4 exercises daily)
Number of subjects: 213
Study 34080544 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol use disorder identification test
Number of subjects: 424
Study 34080544 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing khat
Number of subjects: 424
Study 34080544 — intervention group
Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 424
Study 34080544 — intervention group
Group type: EXPERIMENTAL
Intervention: Having intimate friends who use alcohol
Number of subjects: 424
Study 34080544 — intervention group
Group type: EXPERIMENTAL
Intervention: Being a 2nd year student
Number of subjects: 424
Study 34080544 — intervention group
Group type: EXPERIMENTAL
Intervention: Being a 3rd year student
Number of subjects: 424
Study 34080544 — intervention group
Group type: EXPERIMENTAL
Intervention: Being a 4th year student
Number of subjects: 424
Study 33196555 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 related medical mistrust
Number of subjects: 101
Study 33196555 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative COVID-19 impacts
Number of subjects: 101
Study 32691272 — intervention group
Group type: EXPERIMENTAL
Intervention: Second Step Child Protection Unit (CPU)
Number of subjects: 1132
Study 34965596 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling only (without HA)
Number of subjects: 22
Study 34965596 — intervention group
Group type: EXPERIMENTAL
Intervention: Total masking (without HA)
Number of subjects: 22
Study 34965596 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial masking (without HA)
Number of subjects: 22
Study 34965596 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling only (with HA)
Number of subjects: 22
Study 34965596 — intervention group
Group type: EXPERIMENTAL
Intervention: Total masking (with HA)
Number of subjects: 22
Study 34965596 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial masking (with HA)
Number of subjects: 22
Study 34743112 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency, low-dose training
Number of subjects: 60
Study 34743112 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 34879860 — intervention group
Group type: EXPERIMENTAL
Intervention: SPOC and TBL blended teaching model
Number of subjects: 52
Study 34879860 — intervention group
Group type: COMPARATOR
Intervention: Conventional teaching method
Number of subjects: 52
Study 35618860 — intervention group
Group type: EXPERIMENTAL
Intervention: Holmium-166 microspheres (166Ho-MS) administered after radiofrequency ablation (RFA)
Number of subjects: 10
Study 35618860 — intervention group
Group type: EXPERIMENTAL
Intervention: Holmium-166 microspheres (166Ho-MS)
Number of subjects: 10
Study 33402311 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human collagen hydrogel (RHCH)
Number of subjects: 21
Study 33402311 — intervention group
Group type: COMPARATOR
Intervention: Human-CTLA4-Ig gene-transferred pig skin xenotransplant
Number of subjects: 21
Study 32820879 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriene/Betamethasone Dipropionate foam (Cal/BD foam) QD (Cal 0.005%, BD 0.064%)
Number of subjects: 408
Study 32820879 — intervention group
Group type: COMPARATOR
Intervention: Calcipotriene foam (Cal foam) QD (Cal 0.005%)
Number of subjects: 408
Study 32820879 — intervention group
Group type: COMPARATOR
Intervention: Betamethasone dipropionate foam (BD foam) QD (BD 0.064%)
Number of subjects: 408
Study 32820879 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriene/Betamethasone Dipropionate foam (Cal/BD foam) QD
Number of subjects: 408
Study 32820879 — intervention group
Group type: COMPARATOR
Intervention: Calcipotriene foam (Cal foam) QD
Number of subjects: 408
Study 32820879 — intervention group
Group type: COMPARATOR
Intervention: Betamethasone dipropionate foam (BD foam) QD
Number of subjects: 408
Study 33739982 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative Stepped Care (CSC) intervention
Number of subjects: 1320
Study 33739982 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 1320
Study 34308589 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic suture bridge technique
Number of subjects: 62
Study 34308589 — intervention group
Group type: COMPARATOR
Intervention: Conventional double tunnel suture technique
Number of subjects: 62
Study 32546045 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 10 mg/kg q6h and Acetaminophen 15 mg/kg q6h (4-hour dosing interval)
Number of subjects: 353
Study 32546045 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen 10 mg/kg q6h and Acetaminophen 15 mg/kg q6h (increased dosing interval by 1 hour)
Number of subjects: 353
Study 36076546 — intervention group
Group type: EXPERIMENTAL
Intervention: Naoqingzhiming tablet (180-2160 mg)
Number of subjects: 0
Study 33794532 — intervention group
Group type: EXPERIMENTAL
Intervention: Hatha yoga (twice a week for 10 weeks)
Number of subjects: 31
Study 33794532 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 31
Study 33794532 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Hatha yoga and control)
Number of subjects: 31
Study 35946912 — intervention group
Group type: EXPERIMENTAL
Intervention: Hesperidin (1g/day)
Number of subjects: 129
Study 35946912 — intervention group
Group type: EXPERIMENTAL
Intervention: Diosmin (1g/day)
Number of subjects: 129
Study 35946912 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of hesperidin and diosmin
Number of subjects: 129
Study 35946912 — intervention group
Group type: COMPARATOR
Intervention: Oral hypoglycemics without intervention
Number of subjects: 129
Study 33978907 — intervention group
Group type: EXPERIMENTAL
Intervention: enoxaparin 40 mg every 12 h (up to 50 mg every 12 h if repeat anti-Xa < 0.1 IU/mL)
Number of subjects: 103
Study 33978907 — intervention group
Group type: EXPERIMENTAL
Intervention: enoxaparin 30 mg every 8 h
Number of subjects: 103
Study 33978907 — intervention group
Group type: EXPERIMENTAL
Intervention: enoxaparin 40 mg every 12 h
Number of subjects: 103
Study 33978907 — intervention group
Group type: COMPARATOR
Intervention: Control group (anti-Xa ≥ 0.1 IU/mL)
Number of subjects: 103
Study 33978907 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (anti-Xa < 0.1 IU/mL)
Number of subjects: 103
Study 33212557 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-lung strategy (OLS) with PEEP of 6-8 cm H2O and intermittent recruitment maneuvers (RM)
Number of subjects: 96
Study 33212557 — intervention group
Group type: COMPARATOR
Intervention: NOLS group (without PEEP and RM)
Number of subjects: 96
Study 33212557 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-lung strategy (OLS)
Number of subjects: 96
Study 32303447 — intervention group
Group type: COMPARATOR
Intervention: GLCM homogeneity (NL)
Number of subjects: 54
Study 32303447 — intervention group
Group type: COMPARATOR
Intervention: GLCM contrast (NL)
Number of subjects: 54
Study 32303447 — intervention group
Group type: COMPARATOR
Intervention: GLCM correlation (NL)
Number of subjects: 54
Study 32303447 — intervention group
Group type: COMPARATOR
Intervention: GLCM dissimilarity (NL)
Number of subjects: 54
Study 32303447 — intervention group
Group type: COMPARATOR
Intervention: GLCM energy (NL)
Number of subjects: 54
Study 32303447 — intervention group
Group type: COMPARATOR
Intervention: GLCM entropy (NL)
Number of subjects: 54
Study 32070326 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative assessment, information booklet, additional education, 30-min pulmonary rehabilitation training session, and post-operative pulmonary rehabilitation program
Number of subjects: 500
Study 32070326 — intervention group
Group type: COMPARATOR
Intervention: Pre-operative assessment and information booklet
Number of subjects: 500
Study 35943248 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 32866488 — intervention group
Group type: EXPERIMENTAL
Intervention: Allograft mixed with concentrated growth factor (CGF)
Number of subjects: 10
Study 32866488 — intervention group
Group type: COMPARATOR
Intervention: Allograft
Number of subjects: 10
Study 33281065 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX4 (fluorouracil, leucovorin, oxaliplatin)
Number of subjects: 2145
Study 33281065 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRI (fluorouracil, leucovorin, irinotecan)
Number of subjects: 2145
Study 33095760 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive chemotherapy (PC) with albendazole, coverage ranging from 49% to 85%.
Number of subjects: 13552
Study 33095760 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (no control group mentioned).
Number of subjects: 13552
Study 32529493 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitative treatment (12 sessions, 2/week)
Number of subjects: 59
Study 32936951 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-absorbable polytetrafluoroethylene mesh (CruraSoft®)
Number of subjects: 159
Study 32936951 — intervention group
Group type: COMPARATOR
Intervention: Suture technique
Number of subjects: 159
Study 35716107 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery+PDT
Number of subjects: 125
Study 35716107 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 125
Study 32236522 — intervention group
Group type: EXPERIMENTAL
Intervention: Mat Pilates Training (MPT)
Number of subjects: 28
Study 32236522 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 28
Study 34862753 — intervention group
Group type: EXPERIMENTAL
Intervention: AST-120 (Renamezin®)
Number of subjects: 150
Study 34862753 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 150
Study 33242918 — intervention group
Group type: EXPERIMENTAL
Intervention: Mother-role development program (2-year duration)
Number of subjects: 120
Study 33242918 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 120
Study 35354682 — intervention group
Group type: EXPERIMENTAL
Intervention: Adductor canal block (ACB)
Number of subjects: 66
Study 35354682 — intervention group
Group type: COMPARATOR
Intervention: Intra-articular steroid-lidocaine injection (IASLI)
Number of subjects: 66
Study 33326878 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma‐Informed Guilt Reduction (TrIGR) therapy
Number of subjects: 145
Study 33326878 — intervention group
Group type: COMPARATOR
Intervention: Supportive Care Therapy (SCT)
Number of subjects: 145
Study 33326878 — intervention group
Group type: EXPERIMENTAL
Intervention: TrIGR therapy
Number of subjects: 145
Study 33326878 — intervention group
Group type: COMPARATOR
Intervention: SCT
Number of subjects: 145
Study 35436422 — intervention group
Group type: EXPERIMENTAL
Intervention: NaHCO3 + CAF
Number of subjects: 10
Study 35436422 — intervention group
Group type: EXPERIMENTAL
Intervention: NaHCO3
Number of subjects: 10
Study 35436422 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 34230526 — intervention group
Group type: EXPERIMENTAL
Intervention: Pinaverium 50 mg, three times daily for 4 weeks
Number of subjects: 264
Study 34230526 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 264
Study 34197780 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological dilation
Number of subjects: 889
Study 34197780 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated eyes)
Number of subjects: 889
Study 33260253 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole (125 mg/mL) at 20 mg/kg PO q12h
Number of subjects: 12
Study 33260253 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole benzoate (25 mg/mL) at 20 mg/kg PO q12h
Number of subjects: 12
Study 33260253 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole benzoate (25 mg/mL) at 10 mg/kg PO q12h
Number of subjects: 12
Study 34894707 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic compression performed by family caregivers
Number of subjects: 75
Study 34894707 — intervention group
Group type: COMPARATOR
Intervention: Sham ischemic compression
Number of subjects: 75
Study 34894707 — intervention group
Group type: COMPARATOR
Intervention: Untreated control
Number of subjects: 75
Study 34894707 — intervention group
Group type: COMPARATOR
Intervention: Ischemic compression and sham ischemic compression
Number of subjects: 75
Study 35241363 — intervention group
Group type: EXPERIMENTAL
Intervention: One-on-one intervention consisting of six modules delivered via laptop computers
Number of subjects: 602
Study 33565519 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted MRI/TRUS fusion prostate biopsy + systematic prostate biopsy (combined group)
Number of subjects: 161
Study 33565519 — intervention group
Group type: COMPARATOR
Intervention: Systematic prostate biopsy (systematic group)
Number of subjects: 161
Study 33565519 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted MRI/TRUS fusion prostate biopsy (in combined group)
Number of subjects: 161
Study 33565519 — intervention group
Group type: COMPARATOR
Intervention: Systematic biopsy (in combined group)
Number of subjects: 161
Study 33565519 — intervention group
Group type: COMPARATOR
Intervention: Systematic biopsies (in combined group)
Number of subjects: 161
Study 34420532 — intervention group
Group type: EXPERIMENTAL
Intervention: IMPaCT therapy
Number of subjects: 0
Study 34420532 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study 34292997 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposed to riverbank erosion
Number of subjects: 611
Study 34292997 — intervention group
Group type: COMPARATOR
Intervention: Non-exposed to riverbank erosion
Number of subjects: 611
Study 32461105 — intervention group
Group type: EXPERIMENTAL
Intervention: Tucatinib (300 mg twice daily) in cohort A
Number of subjects: 41
Study 32461105 — intervention group
Group type: EXPERIMENTAL
Intervention: Tucatinib (750 mg once daily) in cohort B
Number of subjects: 41
Study 32461105 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (Tucatinib with trastuzumab)
Number of subjects: 41
Study 35758002 — intervention group
Group type: EXPERIMENTAL
Intervention: ZNF582m/PAX1m test
Number of subjects: 424
Study 35758002 — intervention group
Group type: COMPARATOR
Intervention: Liquid-based cytology (LBC)
Number of subjects: 424
Study 35758002 — intervention group
Group type: EXPERIMENTAL
Intervention: ZNF582m
Number of subjects: 424
Study 35758002 — intervention group
Group type: EXPERIMENTAL
Intervention: PAX1m
Number of subjects: 424
Study 33687651 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic hypoparathyroidism
Number of subjects: 8097
Study 35082253 — intervention group
Group type: EXPERIMENTAL
Intervention: Verum-nVNS
Number of subjects: 56
Study 35082253 — intervention group
Group type: COMPARATOR
Intervention: Sham-nVNS
Number of subjects: 56
Study 35082253 — intervention group
Group type: EXPERIMENTAL
Intervention: nVNS
Number of subjects: 56
Study 34506972 — intervention group
Group type: EXPERIMENTAL
Intervention: Bumetanide treatment for 91 days
Number of subjects: 82
Study 34506972 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 82
Study 35064894 — intervention group
Group type: EXPERIMENTAL
Intervention: Biweekly monitoring/feedbacks (BMF)
Number of subjects: 81
Study 35064894 — intervention group
Group type: EXPERIMENTAL
Intervention: Site-based assistance/mentorship (SAM)
Number of subjects: 81
Study 35064894 — intervention group
Group type: EXPERIMENTAL
Intervention: Both BMF and SAM
Number of subjects: 81
Study 35064894 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 81
Study 33997964 — intervention group
Group type: EXPERIMENTAL
Intervention: Programa Compasso (PC)
Number of subjects: 3018
Study 33686771 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser treatment (Er:YAG and Nd:YAG lasers)
Number of subjects: 53
Study 33686771 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard extraction procedure)
Number of subjects: 53
Study 36128833 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-use flexible cystoscope (Ambu® aScopeTM️ 4 Cysto System)
Number of subjects: 101
Study 36128833 — intervention group
Group type: COMPARATOR
Intervention: Standard reusable flexible cystoscope (Olympus CYF‐VH)
Number of subjects: 101
Study 35666208 — intervention group
Group type: EXPERIMENTAL
Intervention: SuperShelf intervention
Number of subjects: 11
Study 35666208 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 11
Study 33352006 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacuum-formed space maintainer
Number of subjects: 30
Study 33352006 — intervention group
Group type: COMPARATOR
Intervention: Banded space maintainer
Number of subjects: 30
Study 33352006 — intervention group
Group type: EXPERIMENTAL
Intervention: Both vacuum-formed and banded space maintainers
Number of subjects: 30
Study 35383908 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (NIVO) plus ipilimumab (IPI) (3 mg/kg + 1 mg/kg every 3 weeks for 4 cycles)
Number of subjects: 1096
Study 35383908 — intervention group
Group type: COMPARATOR
Intervention: Sunitinib (SUN) (50 mg daily for four 6-week cycles)
Number of subjects: 1096
Study 35383908 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (NIVO) plus ipilimumab (IPI)
Number of subjects: 1096
Study 35383908 — intervention group
Group type: COMPARATOR
Intervention: Sunitinib (SUN)
Number of subjects: 1096
Study 32891516 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 202
Study 32891516 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 202
Study 32891516 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 202
Study 32891516 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 202
Study 33601687 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression + PD
Number of subjects: 397
Study 33601687 — intervention group
Group type: COMPARATOR
Intervention: Depression-only
Number of subjects: 397
Study 33601687 — intervention group
Group type: EXPERIMENTAL
Intervention: PD ± depression
Number of subjects: 397
Study 33934704 — intervention group
Group type: EXPERIMENTAL
Intervention: n‐3 LCPUFA (1 g/day, 694 mg DHA and 397 mg EPA)
Number of subjects: 600
Study 33934704 — intervention group
Group type: COMPARATOR
Intervention: Placebo (corn/soy oil blend)
Number of subjects: 600
Study 33225970 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal extracts (Investigational Product - 1: 400mg, Investigational Product - 2: 450mg)
Number of subjects: 72
Study 33225970 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal extracts (Investigational Product)
Number of subjects: 72
Study 33225970 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigational Product
Number of subjects: 72
Study 33225970 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver Function Test and Kidney Function Test
Number of subjects: 72
Study 33225970 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Edible starch 450mg)
Number of subjects: 72
Study 35121606 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week specific exercise programme
Number of subjects: 100
Study 35121606 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise intervention)
Number of subjects: 100
Study 32112263 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact-based anti-stigma training
Number of subjects: 204
Study 35282787 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented dairy beverage (8 oz containing 25-30 billion colony forming units of live and active kefir cultures)
Number of subjects: 26
Study 35282787 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric, non-fermented, 1% low-fat lactose-free dairy-based control beverage (8 oz)
Number of subjects: 26
Study 35914542 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg tirzepatide
Number of subjects: 443
Study 35914542 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg tirzepatide
Number of subjects: 443
Study 35914542 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg tirzepatide
Number of subjects: 443
Study 35914542 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirzepatide (all doses)
Number of subjects: 443
Study 32498226 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 Diabetes Mellitus (T2DM) prevalence
Number of subjects: 150
Study 32498226 — intervention group
Group type: EXPERIMENTAL
Intervention: High fasting blood glucose level
Number of subjects: 150
Study 32498226 — intervention group
Group type: EXPERIMENTAL
Intervention: High glycosylated hemoglobin
Number of subjects: 150
Study 32498226 — intervention group
Group type: EXPERIMENTAL
Intervention: Age ≥ 50 years association with T2DM
Number of subjects: 150
Study 32498226 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational level association with T2DM
Number of subjects: 150
Study 32498226 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonconsumption of whole grains daily association with T2DM
Number of subjects: 150
Study 32498226 — intervention group
Group type: EXPERIMENTAL
Intervention: High HOMA‐IR association with T2DM
Number of subjects: 150
Study 32498226 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between BMI and glycemic parameters
Number of subjects: 150
Study 35940465 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Itrifal Hakim Ali (IHA) (10g/day) and topical Habb‐e‐Kalaf (HK)
Number of subjects: 72
Study 35940465 — intervention group
Group type: COMPARATOR
Intervention: Oral Itraconazole (100 mg/day) and local Terbinafine (1%)
Number of subjects: 72
Study 32933960 — intervention group
Group type: EXPERIMENTAL
Intervention: Behaviour Change Techniques (BCTs) in intervention groups
Number of subjects: 86